iRadimed reports record Q2 revenue of $12.7M; GAAP EPS $0.26; full-year guidance raised

IRADIMED CORP

2022-Q2 EPS reported $0.45 revenue$25,032,279

Q2 revenue $12.7M vs $9.8M YoY (+30%); GAAP diluted EPS $0.26 vs $0.12; non-GAAP EPS $0.26.
Q3 2022 guidance: revenue $13.1-13.3M, GAAP EPS $0.21-0.24, non-GAAP EPS $0.22-0.25.
Full-year 2022 guidance raised: revenue $52.5-53.2M (from $51.4-52.2M), GAAP EPS $0.89-0.95 (from $0.82-0.90), non-GAAP EPS $0.96-1.03.
Gross margin improved to 79.7% from 76.2%; domestic sales 85% of revenue.
Q2 cash from operations $1.6M vs $3.6M YoY; orders exceeded shipments building backlog.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.